Evaluation of Endometrial Angiogenesis in Mice Uterus Before Implantation in Natural Cycles Followed by Use of Human Menopausal Gonadotropin - Human Chorionic Gonadotropin Drugs and Epigallocatechin Gallate

Abstract

Background: Angiogenesis plays a major role in endometrial receptivity and thickening of the endometrium immediately before implantation. The aim of the present work was to evaluate the antiangiogenic properties of epigallocatechin-3-gallate (EGCG) from green tea in angiogenesis of endometrium. Materials and Methods: In this study, forty adult female NMARI mice randomly divided into four groups. Control group received vehicle; human menopausal gonadotropin/human chorionic gonadotropin (HMG/HCG) group received 7.5 IU HMG intraperitoneal (IP) and 48 h later 7.5 IU HCG was injected (IP) for ovarian stimulation; HMG/HCG + EGCG group received HMG and HCG in the same manner as the previous group and also received 5 mg/kg EGCG at 0, 24, 48, and 72 h after injection of HMG; and the group EGCG received 5 mg/kg EGCG. A male mouse was kept with two female animals in the same cage for mating. Mice were dissected 96 h after administration of HMG (immediately before implantation) and tissue processing was carried out for the uterine specimens. CD31-positive cells were counted by use of histological and immunohistochemical methods. Results: Angiogenesis in EGCG-treated group was less than that of control and gonadotropin group (P < 0.05). The number of endothelial cells was counted by CD31 marker under a light microscope and showed significant differences between all groups (P < 0.05). Conclusion: EGCG significantly inhibited the angiogenesis in endometrium (in natural cycles) through antiangiogenic effects.

Keywords: Angiogenesis, epigallocatechin gallate, human menopausal gonadotropin/human chorionic gonadotropin, implantation

Introduction

Neovascularization in two occurs forms: vasculogenesis and angiogenesis. Vasculogenesis is the process whereby hemangioblasts differentiate into blood cells, and mature endothelial cells and new blood vessel is formed.[1] On the other hand, angiogenesis is the formation of new blood vessel from preexisting vascular networks.[2] Angiogenesis divided into two components: physiological nonphysiological or pathological angiogenesis. Physiological angiogenesis occurs during the process of wound healing and tissue repair, during the formation of ovarian corpus luteum, and placental development establishing pregnancy. Pathological angiogenesis occurs during rheumatoid arthritis, diabetic retinopathy, psoriasis, endometriosis, and tumor growth and metastasis.[3] Endometriosis is a chronic

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

disorder characterized by the implantation of endometrial glands and stroma outside the uterine cavity. Despite different hypotheses regarding the pathogenesis of endometriosis, it is known that angiogenesis plays an important role in the growth and survival of endometriotic lesions and endometriosis is an angiogenesis-dependent disorder.[4] Antiangiogenesis therapy offers a new chance for the treatment of endometriosis.^[5] Bezafibrate, as pan-PPAR agonist, restores angiogenesis in hindlimb ischemic diabetic animals and may be beneficial for the prevention or treatment of peripheral artery disease in diabetic subjects.[6]

Globally, tea is the second most popular beverage after water.^[7] It is consumed in different parts of the world as black, green, and oolong tea. Green tea is

How to cite this article: Rashidi B, Malekzadeh M. Evaluation of Endometrial Angiogenesis in Mice Uterus Before Implantation in Natural Cycles Followed by Use of Human Menopausal Gonadotropin - Human Chorionic Gonadotropin Drugs and Epigallocatechin Gallate. Adv Biomed Res 2017;6:138.

Received: October, 2016. Accepted: October, 2016.

Bahman Rashidi, Mehrnoush Malekzadeh

From the Department of Anatomical Sciences and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Address for correspondence:
Dr. Bahman Rashidi,
Department of Anatomical
Sciences and Molecular Biology,
School of Medicine, Isfahan
University of Medical Sciences,
Isfahan, Iran.
E-mail: b_rashidi@med.mui.
ac.ir

Access this article online

Website: www.advbiores.net

DOI: 10.4103/2277-9175.218029

Quick Response Code:



prepared from the leaves of the tea plant called Camellia sinensis, and the impact of its consumption on several diseases and populations have been reported in clinical studies and laboratory animals.[8] Green tea, which includes 20% of the world's tea consumption, is made by steaming or pan-frying the leaves and then drying them to inactivate enzymes and prevent the oxidation of the tea's components.^[9] These processes preserve the tea polyphenols known as catechins which account for 30%-40% of the dry weight.[10] The main catechins found in green tea include epigallocatechin-3-gallate (EGCG), epicatechin gallate (ECG), epigallocatechin (EGC), and epicatechin.[11] gallocatechin gallate (GCG), catechin gallate, and catechin.[12] EGCG is the most abundant and active catechin in green tea, which accounts for 50%-80% of the catechin content.^[13] The polyphenols found in green tea, especially epigallocatechin-3-gallate (EGCG), have strong antioxidative, antimitotic, and antiangiogenic properties.^[14] The antiangiogenic activity of EGCG has been widely proved in vitro and in vivo.[15] In previous studies, it was reported that EGCG suppressed the angiogenesis signaling pathway and inhibited neovascularization and the growth of experimental endometriosis in mice. [16,17]

Due to the similarity in nature and histologic features of endometrial and endometriosis lesions and considering the fact that angiogenesis plays a major role in endometrial receptivity and thickening of the endometrium immediately before implantation, it is critically important to investigate the study that shows whether the contents of green tea can inhibit angiogenesis and subsequent reduction of implantation. The endometrium is one of the most interesting tissues in the human body.[18] The human endometrium endures a complex series of organized proliferative and secretory alterations in each menstrual cycle, and shows only a short period of receptivity, known as the "window of implantation." [19] All these are affected by ovarian hormones, estrogen, and progesterone. [20] Experts utilized gonadotropin (human menopausal gonadotropin [HMG]/human chorionic gonadotropin [HCG]) to induce ovarian follicle development and luteinizing hormone surge in in vitro fertilization and intracytoplasmic sperm injection procedures.

In the luteal phase, endometrium provided the conditions for implantation. This study aims to survey the effect of gonadotropins and EGCG on angiogenesis in mice endometrium. Platelet endothelial cell adhesion molecule or CD31 is a new marker for the detection of angiovasculogenic activity express in endothelial cells with high levels of angiogenic activity. Due to ethical considerations, animal model was utilized for the preparation of tissue sections. In a review of literature, no study has been carried out on the effect of EGCG on endometrial angiogenesis.

Materials and Methods

Animals

For this study, forty adult female NMRI mice (3 months old) and twenty adult male NMRI mice, weighing about 25–30 g were housed in animal house of Medical School of Isfahan University of Medical Sciences within a temperature-controlled environment on a 12 h/12 h light–dark cycle while water and standard animal food diet were provided *ad libitum*. Female mice were randomly divided into four groups of ten as a control group, receiving HMG/HCG and the recipient of the EGCG with gonadotropin (HMG/HCG) and receiving EGCG group. In all groups, two female mice were placed with a male mouse in a cage for mating for a day.

Drugs

HMG (Ferring, Germany) and HCG (Ferring, Germany) were utilized to artificially induce the growth of ovarian follicles and ovulation. Moreover, EGCG (Sigma, USA) as an antiangiogenic agent was utilized in target groups.

Study interventions

No intervention was done in the control group. Within the groups receiving gonadotropin, the 7.5 IU HMG was injected (intraperitoneally [IP]) and 48 h after injection of HMG, 7.5 IU HCG was injected for ovarian stimulation. In the group receiving the drug substance, at 0, 24, 48, and 72 h after HMG injection, 5 mg per kg EGCG (IP) was injected. The respective doses of EGCG were selected as they had been proven to have significant antiangiogenic effects in mice *in vivo*.^[22] Thereafter, in the whole group, two female mice with a male mouse were placed in a cage for mating. Mice were sacrificed using anesthesia 96 h after HMG administration (immediately before implantation) and 1.3 middle uterus was washed with culture medium.

Histology staining

The uterus of the mice containing blastocyst was sampled. The samples were buffered in 10% formalin for fixation. Thereafter, they underwent stages of tissue processing with ascending grades of alcohol, cleared with xylol, and finally, embedded in paraffin. The samples with 4- μ tissue sections using microtome serial sections were stained with periodic acid-Schiff (PAS) and analyzed utilizing an optical microscope.

Immunohistochemistry staining

Endometrial samples were fixed by 10% Buffered Formalin (Sigma, USA) for 24 h and were subjected to tissue processing with ascending grade of alcohol and transparency in Xylene (Sigma, USA). Finally, they were embedded in paraffin, and 4-μ tissue sections using microtome serial sections (slice vector) were prepared. The immunohistochemistry (IHC) method was utilized to detect angiogenesis in endothelial cells. In this method, the 4-μ

thick slices were removed and placed on slides previously covered with poly-L-lysine in all groups. They were stained by IHC. The basis of this method is that in the first level, antigen binds to the primary antibody, anti-CD31 antibody (AbCam, UK), and then the secondary antibody binds to the primary antibody as its antigen for the second level. Antibody-labeled and antibody complex can be shown using the enzyme substrate. Due to the reaction of peroxidase enzyme with diaminobenzidine (DAB); DAB is utilized as a peroxidase substrate, and a dark brown product is formed.

Statistical analysis

The different field in every mice and the group were randomly determined using microscopes connected to computer with $\times 40$ magnification and Motic Images Advanced 3.2 software (Motic China Group Co., Ltd), and then CD31 positive cell count was performed. Finally, groups were compared in terms of the number of endothelial cells using software SPSS (version 20, SPSS Inc. Chicago, USA). and the Kruskal–Wallis test. As mentioned above, a simple random sampling method was used and the level of statistical significance was set at P < 0.05.

Results

Morphometric and histomorphologic study

In microscopic observation of the uterus in mice; perimetrium, myometrium, endometrium with specified thickness can be clearly seen. Endometrium characterized by myometrium to top of the epithelial cell has different thickness in a different part. In some parts; endometrial thickness which contains stroma, uterine glands, and luminal epithelium is found several times in some part with just a row of epithelium and small amount of stroma. Observation of glandular cells, lumen of the uterus and luminal epithelium folds with larger magnification (×40) revealed that the nucleus of glandular and luminal cells is located in the basal area with abundant extracellular matrix between the stromal cells. All these observations revealed that dropsically endometrium is formed in preimplantation or endometrium window stage [Figure 1]. The glandular epithelium cells in the form of short cylindrical lumen-containing secretions can be seen. The uterine luminal epithelium cells in the form of a cylinder with apical secretory granules and basement membrane is visible [Figure 1].

Immunohistochemistry study

Optical microscopy studies revealed that long columnar luminal epithelial cells with many PAS positive granules are placed mainly in the basal cell surface (in the subnuclear area) in the control group [Figure 2]. In group gonadotropin [Figure 3], the long columnar luminal epithelial cells with many PAS positive granules were in supranuclear and basal area. In the other two groups, EGCG [Figure 4], and gonadotropin + EGCG [Figure 5],




Figure 1: Histological morphology in uterus (luteal phase in all groups). P: Perimetrium, M: Myometrium, E: Endometrium, L: Lumen, LE: Luminal epithelium, GE: Glandular endometrium




Figure 2: CD31-positive cells in control group (×400), endothelial cells are shown with arrows




Figure 3: CD31-positive cells in EGCG group (×400), endothelial cells are shown with arrows

cells were seen as columnar and PAS positive granules in the supranuclear and basal area (in the subnuclear area). In all groups, nucleus was central




Figure 4: CD31-positive cells in human menopausal gonadotropin/human chorionic gonadotropin group (×400), endothelial cells are shown with arrows

and seemed to be vacuolated, which represents the luteal phase of endometrium.

Moreover, the results from Kruskal–Wallis test reveal that the difference between the mean of CD31 positive cells in all groups was significant [P < 0.05, Figure 6].

According to our findings, the mean of CD31 positive cells were 31.85 ± 3.53 in control group, 43.08 ± 3.96 in gonadotropin group, 15.90 ± 3.83 in gonadotropin + EGCG group, and 19.53 ± 4.72 in EGCG group. The results showed that angiogenesis parameter can be affected by exogenous factors such as gonadotropins and EGCG. The utilization of gonadotropins in the ovulation-stimulating process increased angiogenesis in this group in comparison with control group. In the other group, the use of gonadotropins + EGCG led to a reduction in the angiogenesis when compared with gonadotropins and control group. According to these results, the inhibitory role of EGCG and activating role of gonadotropins on angiogenesis can be inferred.

Discussion

The results of this study indicate that EGCG with a dose of 5 mg/kg after different durations (before implantation) in receiving EGCG groups (EGCG and EGCG + gonadotropin groups) inhibit angiogenesis in uterus of mice in comparison with nonreceiving groups (control and gonadotropin groups). The utilization of gonadotropins in the ovulation-stimulating process increased angiogenesis in this group in comparison with control group [Figures 1 and 2]. In the other group, the use of gonadotropins + EGCG led to a reduction in the angiogenesis when compared with gonadotropins group. The comparison of gonadotropins + EGCG and EGCG group demonstrated that angiogenesis in gonadotropins + EGCG is lower than EGCG group. Our results had many similarities with the results of studies of EGCG on endometriosis lesions.^[16] Optical microscopy studies revealed that PAS




Figure 5: CD31-positive cells in human menopausal gonadotropin/human chorionic gonadotropin + EGCG group (×400), endothelial cells are shown with arrows

positive granules are mainly placed in the basal cell surface in the control group, while PAS positive granules are placed in supranuclear and subnuclear area in other groups.

Xu *et al.* in 2009 reported that EGCG with dose of 50 mg/kg IP has antiangiogenic effects on an experimental endometriosis mouse model. Although Nakae, *et al.* in 2008 demonstrated the dose-dependent antiangiogenic effects, they proved that EGCG at the lower dose of 5 mg/kg IP also had the same result. Since all previous studies were on endometriosis and no study has been carried out on the effect of EGCG on endometrium yet; therefore, the minimum dose was used (5 mg/kg) as the first study on uterine endometrium.

In general, angiogenesis is the growth of new vascular capillary channels from preexisting vessels. Angiogenesis is regulated by the balance between a huge number of pro- and anti-angiogenic factors. Three families of receptor protein-tyrosine kinases are involved in vasculogenesis and angiogenesis. The vascular endothelial growth factor/vascular endothelial growth factor receptor (VEGF/VEGFR) family is the most important regulator of vascular development. The angiopoietin-Tie system controls vessel maturation and quiescence while the eph-Ephrin system controls positional conduction cues and arterio-venous asymmetry. [25]

Lee, et al. in 2014 reported that epigalloccatechin-3-gallate inhibits neovascularization and vascular permeability through the suppression of MMP-9 and VEGF activation. [26]

Cerezo-Guisado, *et al.* in 2015 reported that EGCG-induced cell death is partially blocked by inhibiting Akt, ERK1/2 activity. PI3K/Akt and MAPK/ERK pathways regulate HIF-1 α protein synthesis which strongly activates VEGF expression. Moreover, the only catechin that can inhibit VEGF binding to its receptor is EGCG. [28]




Figure 6: Graphical comparison of four groups with the mean ± standard deviation that shows significant difference between the four groups. As indicated, there is a significant difference between the four groups (P < 0.05). These symbols demonstrated different group (*+#). (*) Significant difference between control group with EGCG group, menopausal gonadotropin/human chorionic gonadotropin group and human menopausal gonadotropin/human chorionic gonadotropin + EGCG group. (+) Significant difference between EGCG group with menopausal gonadotropin/human chorionic gonadotropin group and human menopausal gonadotropin/human chorionic gonadotropin/human chorionic gonadotropin/human chorionic gonadotropin group with human menopausal gonadotropin/human chorionic gonadotropin group with human menopausal gonadotropin/human chorionic gonadotropin + EGCG group

Deng, *et al.* in 2013 concluded that EGCG leads to a reduction in interstitial fluid pressure and hypoxia and improve chemotherapy efficacy through rebalance of Ang-1 and Ang-2.^[29] Ephrin (Eph) is a third critical mediator of angiogenesis.^[30] Tang, *et al.* in 2007 indicated that activation of ERK-1/2 plays an essential role in ephrin-A1-mediated cell migration. EGCG inhibited ephrin-A1-mediated endothelial migration and angiogenesis.^[31] On the other hand, EGCG can arrest cell cycle^[32] and induce apoptosis^[33] and cell death.^[34]

In summary, green tea inhibits angiogenesis through several mechanisms: cell cycle arrest, [32] induction of apoptosis, [35] reduced expression of VEGF, [2] inhibition of VEGF/VEGFR, [28] inhibition of phosphorylation of VEGFR. Since EGCG has been reported to inhibit angiogenesis in endometriosis, [16] we decided to investigate the effects of EGCG on angiogenesis of endometrium.

According to the previous study, EGCG significantly inhibited the development of endometriosis through antiangiogenic effects. [16] It is well knowing that angiogenesis plays a major role in endometrial maturation and thickening of the endometrium before implantation. In this study, it was concluded that green tea can inhibit angiogenesis and endometrial implantation which is followed by a decline. Since no study about molecular pathway of EGCG on endothelial cells of endometrium has been reported, it is therefore recommended that more studies should be carried out.

Conclusion

Angiogenesis plays an essential role in endometrial thickness, its increase or decrease can be effective in fertility and infertility. Therefore, our study suggested that because EGCG has a significant inhibitory effect on the development of endometrium, women who are planning for pregnancy should avoid it due to the severity of its limitations.

Acknowledgments

Our appreciation goes to the School of Medicine, Isfahan University of Medical Science for helping to fund this research.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

- Dvorak HF. Angiogenesis: Update 2005. J Thromb Haemost 2005;3:1835-42.
- Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.
- Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 2004;25:581-611.
- Taylor RN, Lebovic DI, Mueller MD. Angiogenic factors in endometriosis. Ann N Y Acad Sci 2002;955:89-100.
- Hull ML, Charnock-Jones DS, Chan CL, Bruner-Tran KL, Osteen KG, Tom BD, et al. Antiangiogenic agents are effective inhibitors of endometriosis. J Clin Endocrinol Metab 2003;88:2889-99.
- Khazaei M, Salehi E, Rashidi B. Pan-PPAR agonist, bezafibrate, restores angiogenesis in hindimb ischemia in normal and diabetic rats. Res Pharm Sci 2012;7:S962.
- Heiss ML, Heiss RJ. The Story of Tea: A Cultural History and Drinking Guide. Ten Speed Press: Penguin Random House; 2007.
- Jurgens TM, Whelan AM, Killian L, Doucette S, Kirk S, Foy E. Green tea for weight loss and weight maintenance in overweight or obese adults. Cochrane Database Syst Rev 2012;12:CD008650.
- Pae M, Wu D. Immunomodulating effects of epigallocatechin-3-gallate from green tea: Mechanisms and applications. Food Funct 2013;4:1287-303.
- Balentine DA, Wiseman SA, Bouwens LC. The chemistry of tea flavonoids. Crit Rev Food Sci Nutr 1997;37:693-704.
- Lakenbrink C, Lapczynski S, Maiwald B, Engelhardt UH. Flavonoids and other polyphenols in consumer brews of tea and other caffeinated beverages. J Agric Food Chem 2000;48:2848-52.
- 12. Miura S, Watanabe J, Tomita T, Sano M, Tomita I. The inhibitory effects of tea polyphenols (flavan-3-ol derivatives) on Cu2+mediated oxidative modification of low density lipoprotein. Biol Pharm Bull 1994;17:1567-72.
- 13. Yang CS, Maliakal P, Meng X. Inhibition of carcinogenesis by tea. Annu Rev Pharmacol Toxicol 2002;42:25-54.
- 14. Nagle DG, Ferreira D, Zhou YD.

- Epigallocatechin-3-gallate (EGCG): Chemical and biomedical perspectives. Phytochemistry 2006;67:1849-55.
- Cao Y, Cao R. Angiogenesis inhibited by drinking tea. Nature 1999;398;381.
- Xu H, Lui WT, Chu CY, Ng PS, Wang CC, Rogers MS. Anti-angiogenic effects of green tea catechin on an experimental endometriosis mouse model. Hum Reprod 2009;24:608-18.
- 17. Xu H, Becker CM, Lui WT, Chu CY, Davis TN, Kung AL, et al. Green tea epigallocatechin-3-gallate inhibits angiogenesis and suppresses vascular endothelial growth factor C/vascular endothelial growth factor receptor 2 expression and signaling in experimental endometriosis in vivo. Fertil Steril 2011;96:1021-8.
- Revel A. Defective endometrial receptivity. Fertil Steril 2012;97:1028-32.
- 19. Strowitzki T, Germeyer A, Popovici R, von Wolff M. The human endometrium as a fertility-determining factor. Hum Reprod Update 2006;12:617-30.
- Paulson RJ. Hormonal induction of endometrial receptivity. Fertil Steril 2011;96:530-5.
- Oliveira JB, Baruffi RL, Mauri AL, Petersen CG, Borges MC, Franco JG Jr. Endometrial ultrasonography as a predictor of pregnancy in an *in-vitro* fertilization programme after ovarian stimulation and gonadotrophin-releasing hormone and gonadotrophins. Hum Reprod 1997;12:2515-8.
- 22. Nakae Y, Hirasaka K, Goto J, Nikawa T, Shono M, Yoshida M, et al. Subcutaneous injection, from birth, of epigallocatechin-3-gallate, a component of green tea, limits the onset of muscular dystrophy in mdx mice: A quantitative histological, immunohistochemical and electrophysiological study. Histochem Cell Biol 2008;129:489-501.
- Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005;438:932-6.
- Eklund L, Olsen BR. Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling. Exp Cell Res 2006;312:630-41.
- Héroult M, Schaffner F, Augustin HG. Eph receptor and ephrin ligand-mediated interactions during angiogenesis and tumor progression. Exp Cell Res 2006;312:642-50.
- Lee HS, Jun JH, Jung EH, Koo BA, Kim YS. Epigalloccatechin-3-gallate inhibits ocular neovascularization and

- vascular permeability in human retinal pigment epithelial and human retinal microvascular endothelial cells via suppression of MMP-9 and VEGF activation. Molecules 2014;19:12150-72.
- Cerezo-Guisado MI, Zur R, Lorenzo MJ, Risco A, Martín-Serrano MA, Alvarez-Barrientos A, et al. Implication of Akt, ERK1/2 and alternative p38MAPK signalling pathways in human colon cancer cell apoptosis induced by green tea EGCG. Food Chem Toxicol 2015;84:125-32.
- 28. Shirakami Y, Shimizu M, Adachi S, Sakai H, Nakagawa T, Yasuda Y, et al. (-)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis. Cancer Sci 2009;100:1957-62.
- Deng PB, Hu CP, Xiong Z, Yang HP, Li YY. Treatment with EGCG in NSCLC leads to decreasing interstitial fluid pressure and hypoxia to improve chemotherapy efficacy through rebalance of Ang-1 and Ang-2. Chin J Nat Med 2013;11:245-53.
- Gale NW, Yancopoulos GD. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 1999;13:1055-66.
- Tang FY, Chiang EP, Shih CJ. Green tea catechin inhibits ephrin-A1-mediated cell migration and angiogenesis of human umbilical vein endothelial cells. J Nutr Biochem 2007;18:391-9.
- Shankar S, Suthakar G, Srivastava RK. Epigallocatechin-3-gallate inhibits cell cycle and induces apoptosis in pancreatic cancer. Front Biosci 2007;12:5039-51.
- 33. Tang GQ, Yan TQ, Guo W, Ren TT, Peng CL, Zhao H, et al. (-)-Epigallocatechin-3-gallate induces apoptosis and suppresses proliferation by inhibiting the human Indian Hedgehog pathway in human chondrosarcoma cells. J Cancer Res Clin Oncol 2010;136:1179-85.
- 34. Huang Y, Kumazoe M, Bae J, Yamada S, Takai M, Hidaka S, *et al.* Green tea polyphenol epigallocatechin-O-gallate induces cell death by acid sphingomyelinase activation in chronic myeloid leukemia cells. Oncol Rep 2015;34:1162-8.
- Kondo T, Ohta T, Igura K, Hara Y, Kaji K. Tea catechins inhibit angiogenesis in vitro, measured by human endothelial cell growth, migration and tube formation, through inhibition of VEGF receptor binding. Cancer Lett 2002;180:139-44.